Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024HemaSphereOpen Access

Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa

View Full Paper
Ask AI
Bookmark
Share

Authors

HRHosuk RyouKSKorsuk SirinukunwattanaRWRuby Wood

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ryou et al. (2024) studied this question.

synapsesocial.com/papers/68e66b2fb6db6435875f6da9https://doi.org/10.1002/hem3.105
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial2024 · 2 citations
  2. 2Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis2016 · 153 citations
  3. 3Quantitative interpretation of bone marrow biopsies in <scp>MPN</scp>—What's the point in a molecular age?2023 · 16 citations
  4. 4Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib2022 · 8 citations
  5. 5The Development of Serum Amyloid P as a Possible Therapeutic2018 · 93 citations